Two Sigma Advisers LP Decreases Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Two Sigma Advisers LP decreased its holdings in shares of Scholar Rock Holding Co. (NASDAQ:SRRK) by 55.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 261,400 shares of the company’s stock after selling 330,600 shares during the period. Two Sigma Advisers LP’s holdings in Scholar Rock were worth $11,298,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in SRRK. Vanguard Group Inc. raised its stake in Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock valued at $205,013,000 after purchasing an additional 708,817 shares during the last quarter. Principal Financial Group Inc. acquired a new position in Scholar Rock in the 4th quarter valued at $274,000. Blackstone Inc. acquired a new position in Scholar Rock in the 4th quarter valued at $910,000. Rhumbline Advisers raised its stake in Scholar Rock by 13.2% in the 4th quarter. Rhumbline Advisers now owns 113,261 shares of the company’s stock valued at $4,895,000 after purchasing an additional 13,247 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Scholar Rock in the 4th quarter valued at $2,625,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, Director Katie Peng sold 1,006 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the sale, the director now owns 30,319 shares in the company, valued at approximately $1,043,579.98. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tracey Sacco sold 6,500 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the sale, the insider now owns 71,750 shares of the company’s stock, valued at approximately $2,373,490. This represents a 8.31% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 154,798 shares of company stock worth $5,482,238. 13.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, Wedbush reissued an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Wednesday, May 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $42.67.

Scholar Rock Stock Performance

Shares of Scholar Rock stock opened at $30.46 on Friday. Scholar Rock Holding Co. has a one year low of $6.76 and a one year high of $46.98. The company has a market cap of $2.89 billion, a PE ratio of -12.96 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The business has a 50-day simple moving average of $30.85 and a 200-day simple moving average of $35.93.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period in the previous year, the firm posted ($0.59) earnings per share. On average, equities research analysts forecast that Scholar Rock Holding Co. will post -2.42 EPS for the current fiscal year.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.